M
Martin F. Fey
Researcher at University of Bern
Publications - 225
Citations - 14420
Martin F. Fey is an academic researcher from University of Bern. The author has contributed to research in topics: Myeloid & Cellular differentiation. The author has an hindex of 64, co-authored 222 publications receiving 13667 citations. Previous affiliations of Martin F. Fey include Scripps Research Institute & Harvard University.
Papers
More filters
Journal ArticleDOI
A Randomized Comparison of All Transretinoic Acid (ATRA) Followed by Chemotherapy and ATRA Plus Chemotherapy and the Role of Maintenance Therapy in Newly Diagnosed Acute Promyelocytic Leukemia
Pierre Fenaux,Claude Chastang,Sylvie Chevret,Miguel A. Sanz,Hervé Dombret,Eric Archimbaud,Martin F. Fey,Consuelo Rayon,Françoise Huguet,Jean-Jacques Sotto,Claude Gardin,Pascale Cony Makhoul,Philippe Travade,Eric Solary,Nathalie Fegueux,Dominique Bordessoule,Jesús F. San Miguel,Harmut Link,Bernard Desablens,Aspasia Stamatoullas,E. Deconinck,Frédéric Maloisel,Sylvie Castaigne,Claude Preudhomme,Laurent Degos +24 more
TL;DR: It is strongly suggest that early addition of chemotherapy to ATRA and maintenance therapy combining continuous CT and intermittent ATRA can reduce the incidence of relapse in APL.
Journal ArticleDOI
Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule
Michele Ghielmini,Shu Fang Hsu Schmitz,Sergio Cogliatti,Gabriella Pichert,Jörg Hummerjohann,Ursula Waltzer,Martin F. Fey,Daniel Betticher,Giovanni Martinelli,Fedro A. Peccatori,Urs Hess,Emanuele Zucca,Roger Stupp,Tibor Kovacsovics,Claudine Helg,Andreas Lohri,Mario Bargetzi,Daniel Vorobiof,Thomas Cerny +18 more
TL;DR: In patients with FL, the administration of 4 additional doses of rituximab at 8-week intervals significantly improves the EFS andCirculating normal B lymphocytes and immunoglobulin M plasma levels decreased for a significantly longer time after prolonged treatment, but the incidence of adverse events was not increased.
Journal ArticleDOI
Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials.
Julia Bohlius,Kurt Schmidlin,Corinne Brillant,Guido Schwarzer,Sven Trelle,Jerome Seidenfeld,Marcel Zwahlen,Mike Clarke,Mike Clarke,Olaf Weingart,Sabine Kluge,Margaret Piper,Dirk Rades,David P. Steensma,Benjamin Djulbegovic,Martin F. Fey,Isabelle Ray-Coquard,Mitchell Machtay,Volker Moebus,Gillian Thomas,Michael Untch,Martin Schumacher,Matthias Egger,Andreas Engert +23 more
TL;DR: Treatment with erythropoiesis-stimulating agents in patients with cancer increased mortality during active study periods and worsened overall survival, and the increased risk of death associated with treatment with these drugs should be balanced against their benefits.
Journal ArticleDOI
Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?
Jan J. Cornelissen,Wim L.J. van Putten,Leo F. Verdonck,Matthias Theobald,Emanuel Jacky,Simon Daenen,Marinus van Marwijk Kooy,Pierre W. Wijermans,Harry C. Schouten,Peter C. Huijgens,Hans van der Lelie,Martin F. Fey,Augustin Ferrant,Johan Maertens,Alois Gratwohl,Bob Löwenberg +15 more
TL;DR: A significant benefit of 12% in overall survival (OS) by donor availability for all patients with AML in CR1 without a favorable cytogenetic profile is revealed.
Journal ArticleDOI
Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia.
Bob Löwenberg,Wim L.J. van Putten,Matthias Theobald,Gmür J,Leo F. Verdonck,Pieter Sonneveld,Martin F. Fey,Harry C. Schouten,Georgine E. de Greef,Augustin Ferrant,Tibor Kovacsovics,Alois Gratwohl,Simon Daenen,Peter C. Huijgens,Marc Boogaerts +14 more
TL;DR: Sensation of leukemic cells with growth factors is a clinically applicable means of enhancing the efficacy of chemotherapy in patients with AML and does not improve the outcome in the subgroup with an unfavorable prognosis.